Zim Laboratories Ltd (ZIMLAB) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1000979,
    "name": "Zim Laboratories",
    "stock_name": "Zim Laboratories",
    "full_name": "Zim Laboratories Ltd",
    "name_url": "stocks-analysis/zim-laboratories",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "70.80",
    "chg": -0.35,
    "chgp": "-0.49%",
    "dir": -1,
    "prev_price": "71.15",
    "mcapval": "344.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 541400,
    "symbol": "ZIMLAB",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE518E01015",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "3.4 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/zim-laboratories-1000979-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Zim Laboratories Sees Revision in Market Assessment Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/zim-laboratories-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-trends-3741304",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ZimLaboratories_mojoScore_3741304.png",
        "date": "2025-12-02 10:09:20",
        "description": "Zim Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The stock has faced persistent headwinds, with recent assessment changes highlighting concerns across multiple performance parameters."
      },
      {
        "title": "Zim Laboratories Faces Intense Selling Pressure Amid Consecutive Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zim-laboratories-faces-extreme-selling-pressure-amid-lower-circuit-lockdown-3733050",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZimLaboratories_only_sellers_3733050.png",
        "date": "2025-11-27 09:51:01",
        "description": "Zim Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, is currently experiencing severe selling pressure with no buyers in the queue, signalling distress selling and a challenging market environment for the stock."
      },
      {
        "title": "Zim Laboratories Faces Selling Pressure with Year-to-Date Losses of 31.56% Amid Declines",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zim-laboratories-faces-selling-pressure-with-year-to-date-losses-of-3156-amid-declines-3706593",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZimLaboratories_only_sellers_3706593.png",
        "date": "2025-11-17 09:31:19",
        "description": "Zim Laboratories Ltd is experiencing significant selling pressure, marked by consecutive days of losses. While it has shown a modest weekly gain, its longer-term performance is troubling, with notable declines over three months, year-to-date, and the past year, reflecting broader market trends and potential company-specific challenges."
      },
      {
        "title": "Zim Laboratories Faces Financial Challenges Amidst Mixed Market Performance Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zim-laboratories-financial-trend-improves-from-very-negative-to-negative-despite-ongoing-challenges-3701291",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZimLaboratories_fintrenddot_3701291.png",
        "date": "2025-11-14 11:03:00",
        "description": "Zim Laboratories has reported a challenging financial quarter ending September 2025, with significant declines in profit before tax and profit after tax. Key metrics show low return on capital employed and reduced cash reserves, alongside a rising debt-equity ratio, indicating heightened financial concerns amid mixed market performance."
      },
      {
        "title": "Zim Laboratories Q2 FY26: Losses Deepen Amid Revenue Recovery",
        "link": "https://www.marketsmojo.com/news/result-analysis/zim-laboratories-q2-fy26-losses-deepen-amid-revenue-recovery-3715240",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZimLaboratories_quaterlyResult_3715240.png",
        "date": "2025-11-14 09:41:05",
        "description": "Zim Laboratories Ltd., a Nagpur-based pharmaceutical formulations manufacturer, reported a net loss of ₹0.42 crores for Q2 FY26, marking a sharp deterioration from the previous quarter's loss of ₹1.87 crores and reversing the profit of ₹2.38 crores recorded in Q2 FY25. The company, with a market capitalisation of ₹354.00 crores, saw its stock trading at ₹74.33 on November 14, 2025, down 31.11% over the past year despite a modest 1.79% gain on the day."
      },
      {
        "title": "How has been the historical performance of Zim Laboratories?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-zim-laboratories-3699536",
        "imagepath": "",
        "date": "2025-11-13 23:40:30",
        "description": "Answer:\nThe historical performance of Zim Laboratories shows a fluctuating trend in key financial metrics over the years.\n\nBreakdown:\nZim Laboratories reported net sales of 379.03 Cr for the year ending March 2025, a slight increase from 367.42 Cr in March 2024, but a decrease from 398.53 Cr in March 2023. The total operating income followed a similar pattern, reaching 379.03 Cr in March 2025. The raw material costs decreased to 155.00 Cr in March 2025 from 177.70 Cr in March 2024, while employee costs increased to 60.76 Cr from 53.34 Cr. Total expenditure, excluding depreciation, was 335.31 Cr in March 2025, up from 326.09 Cr in March 2024. Operating profit (PBDIT) was 49.50 Cr in March 2025, showing a rise from 46.51 Cr in March 2024, but down from 58.40 Cr in March 2023. Profit before tax decreased to 18.01 Cr in March 2025 from 23.64 Cr in March 2024, and profit after tax also fell to 12.17 Cr from 17.2..."
      },
      {
        "title": "Why is Zim Laboratories falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-zim-laboratories-fallingrising-3699055",
        "imagepath": "",
        "date": "2025-11-13 23:21:31",
        "description": "As of 13-Nov, Zim Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 72.67, which reflects a decrease of Rs 4.23 or 5.5%. The stock has been underperforming, having fallen consecutively for the last two days with a total decline of 6.38%. It opened the day with a significant loss of 3.42% and reached an intraday low of Rs 72.11. Additionally, the stock's delivery volume has drastically decreased by 89.76% compared to the 5-day average, indicating a drop in investor participation. Over the longer term, the stock has shown a year-to-date decline of 32.08%, which is considerably worse than the Sensex's gain of 8.11% during the same period.\n\nIn the broader market context, Zim Laboratories' short-term performance over the past week shows a modest gain of 2.60%, which is better than the Sensex's increase of 1.40%. However, this positive short-term return is overshadowed by the stock's ..."
      },
      {
        "title": "How has been the historical performance of Zim Laboratories?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-zim-laboratories-3695563",
        "imagepath": "",
        "date": "2025-11-13 00:30:16",
        "description": "Answer:\nThe historical performance of Zim Laboratories shows a mixed trend in key financial metrics over the years.\n\nBreakdown:\nZim Laboratories reported net sales of 379.03 Cr for the year ending March 2025, reflecting a slight increase from 367.42 Cr in March 2024 but a decrease from 398.53 Cr in March 2023. The total operating income for March 2025 was also 379.03 Cr, with total expenditure (excluding depreciation) at 335.31 Cr, leading to an operating profit (PBDIT) of 49.50 Cr. This was a rise from 46.51 Cr in March 2024 but a decline from 58.40 Cr in March 2023. The profit before tax decreased to 18.01 Cr in March 2025 from 23.64 Cr in March 2024 and 35.36 Cr in March 2023, while the profit after tax was reported at 12.17 Cr, down from 17.25 Cr in the previous year and 24.43 Cr in March 2023. The earnings per share (EPS) for March 2025 was 2.5, a decline from 3.54 in March 2024 and 5.01 in March 2023...."
      },
      {
        "title": "Why is Zim Laboratories falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-zim-laboratories-fallingrising-3691337",
        "imagepath": "",
        "date": "2025-11-11 23:27:05",
        "description": "As of 11-Nov, Zim Laboratories Ltd's stock price is currently at 77.62, reflecting an increase of 7.15 or 10.15%. The stock has shown strong performance today, outperforming its sector by 10.28% and reaching an intraday high of Rs 79.83, which is a rise of 13.28%. Despite this positive movement, the stock has experienced high volatility with an intraday volatility of 8.54%. Over the past week, the stock has gained 5.86%, and over the past month, it has increased by 8.45%. However, it is important to note that the stock's year-to-date performance is down by 27.46%, indicating a significant decline over a longer period. There is no information available regarding positive or negative factors impacting the stock's recent movement.\n\nIn the broader market context, Zim Laboratories' short-term performance has significantly outpaced the benchmark Sensex, which has only risen by 0.49% over the past week and 1.66% o..."
      }
    ],
    "total": 485,
    "sid": "1000979",
    "stock_news_url": "https://www.marketsmojo.com/news/zim-laboratories-1000979"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "03-Dec-2025",
      "details": "Press release for grant of permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole received from CDSCO - Directorate General Health Services to the Company",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "17-Nov-2025",
      "details": "Please find enclosed transcript of earnings call held on 14th November 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "15-Nov-2025",
      "details": "Please find enclosed herewith the link of audio recording of the earnings call held on 14th Novemeber 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Zim Laboratories Ltd has declared <strong>5%</strong> dividend, ex-date: 19 Sep 19",
          "dt": "2019-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Zim Laboratories Ltd has announced <strong>2:1</strong> bonus issue, ex-date: 22 Dec 22",
          "dt": "2022-12-22",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Zim Laboratories Sees Revision in Market Assessment Amidst Challenging Fundamentals

2025-12-02 10:09:20

Zim Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The stock has faced persistent headwinds, with recent assessment changes highlighting concerns across multiple performance parameters.

Zim Laboratories Faces Intense Selling Pressure Amid Consecutive Losses

2025-11-27 09:51:01

Zim Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, is currently experiencing severe selling pressure with no buyers in the queue, signalling distress selling and a challenging market environment for the stock.

Zim Laboratories Faces Selling Pressure with Year-to-Date Losses of 31.56% Amid Declines

2025-11-17 09:31:19

Zim Laboratories Ltd is experiencing significant selling pressure, marked by consecutive days of losses. While it has shown a modest weekly gain, its longer-term performance is troubling, with notable declines over three months, year-to-date, and the past year, reflecting broader market trends and potential company-specific challenges.

Zim Laboratories Faces Financial Challenges Amidst Mixed Market Performance Trends

2025-11-14 11:03:00

Zim Laboratories has reported a challenging financial quarter ending September 2025, with significant declines in profit before tax and profit after tax. Key metrics show low return on capital employed and reduced cash reserves, alongside a rising debt-equity ratio, indicating heightened financial concerns amid mixed market performance.

Zim Laboratories Q2 FY26: Losses Deepen Amid Revenue Recovery

2025-11-14 09:41:05

Zim Laboratories Ltd., a Nagpur-based pharmaceutical formulations manufacturer, reported a net loss of ₹0.42 crores for Q2 FY26, marking a sharp deterioration from the previous quarter's loss of ₹1.87 crores and reversing the profit of ₹2.38 crores recorded in Q2 FY25. The company, with a market capitalisation of ₹354.00 crores, saw its stock trading at ₹74.33 on November 14, 2025, down 31.11% over the past year despite a modest 1.79% gain on the day.

How has been the historical performance of Zim Laboratories?

2025-11-13 23:40:30

Answer: The historical performance of Zim Laboratories shows a fluctuating trend in key financial metrics over the years. Breakdown: Zim Laboratories reported net sales of 379.03 Cr for the year ending March 2025, a slight increase from 367.42 Cr in March 2024, but a decrease from 398.53 Cr in March 2023. The total operating income followed a similar pattern, reaching 379.03 Cr in March 2025. The raw material costs decreased to 155.00 Cr in March 2025 from 177.70 Cr in March 2024, while employee costs increased to 60.76 Cr from 53.34 Cr. Total expenditure, excluding depreciation, was 335.31 Cr in March 2025, up from 326.09 Cr in March 2024. Operating profit (PBDIT) was 49.50 Cr in March 2025, showing a rise from 46.51 Cr in March 2024, but down from 58.40 Cr in March 2023. Profit before tax decreased to 18.01 Cr in March 2025 from 23.64 Cr in March 2024, and profit after tax also fell to 12.17 Cr from 17.2...

Why is Zim Laboratories falling/rising?

2025-11-13 23:21:31

As of 13-Nov, Zim Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 72.67, which reflects a decrease of Rs 4.23 or 5.5%. The stock has been underperforming, having fallen consecutively for the last two days with a total decline of 6.38%. It opened the day with a significant loss of 3.42% and reached an intraday low of Rs 72.11. Additionally, the stock's delivery volume has drastically decreased by 89.76% compared to the 5-day average, indicating a drop in investor participation. Over the longer term, the stock has shown a year-to-date decline of 32.08%, which is considerably worse than the Sensex's gain of 8.11% during the same period. In the broader market context, Zim Laboratories' short-term performance over the past week shows a modest gain of 2.60%, which is better than the Sensex's increase of 1.40%. However, this positive short-term return is overshadowed by the stock's ...

How has been the historical performance of Zim Laboratories?

2025-11-13 00:30:16

Answer: The historical performance of Zim Laboratories shows a mixed trend in key financial metrics over the years. Breakdown: Zim Laboratories reported net sales of 379.03 Cr for the year ending March 2025, reflecting a slight increase from 367.42 Cr in March 2024 but a decrease from 398.53 Cr in March 2023. The total operating income for March 2025 was also 379.03 Cr, with total expenditure (excluding depreciation) at 335.31 Cr, leading to an operating profit (PBDIT) of 49.50 Cr. This was a rise from 46.51 Cr in March 2024 but a decline from 58.40 Cr in March 2023. The profit before tax decreased to 18.01 Cr in March 2025 from 23.64 Cr in March 2024 and 35.36 Cr in March 2023, while the profit after tax was reported at 12.17 Cr, down from 17.25 Cr in the previous year and 24.43 Cr in March 2023. The earnings per share (EPS) for March 2025 was 2.5, a decline from 3.54 in March 2024 and 5.01 in March 2023....

Why is Zim Laboratories falling/rising?

2025-11-11 23:27:05

As of 11-Nov, Zim Laboratories Ltd's stock price is currently at 77.62, reflecting an increase of 7.15 or 10.15%. The stock has shown strong performance today, outperforming its sector by 10.28% and reaching an intraday high of Rs 79.83, which is a rise of 13.28%. Despite this positive movement, the stock has experienced high volatility with an intraday volatility of 8.54%. Over the past week, the stock has gained 5.86%, and over the past month, it has increased by 8.45%. However, it is important to note that the stock's year-to-date performance is down by 27.46%, indicating a significant decline over a longer period. There is no information available regarding positive or negative factors impacting the stock's recent movement. In the broader market context, Zim Laboratories' short-term performance has significantly outpaced the benchmark Sensex, which has only risen by 0.49% over the past week and 1.66% o...

View All News